Covid-19 Vaccine Responsiveness in MM and Waldenstrom

What's the purpose of this trial?

COVID-19 vaccines are designed to help prevent infections, hospitalizations, and death from the COVID-19 virus. Normally, when the vaccine is administered, the immune system reacts by creating antibodies (proteins made by the body's immune system to fight infections such as COVID-19) and helping the immune system's blood cells to fight it. In people with Multiple Myeloma and Waldenstrom's Macroglobulinemia, their immune system does not function normally, and an effective immune response may not occur. The research study procedures include screening for eligibility and the collection of data and biospecimens. It is expected that about 160 people will take part in this research study.

This is an upcoming trial that has not yet started accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Age >18 years
  • Lack of a contra-indication to a currently available COVID-19 vaccine.
  • Diagnosis of MM according to International Myeloma Working Group (IWMG) criteria (Cohort 1) or Diagnosis of WM according to WHO criteria (Cohort 2)
  • For treatment naïve WM patients (Cohort 2A):
    • Patient must have no prior history of anticancer treatment for WM.
    • The treating investigator must have no intention to initiate WM therapy within 2 months
  • For WM patients receiving BTK inhibitor (Cohort 2B):
    • Patient must have no history of cytotoxic chemotherapy within 1 year, and no history of other anticancer therapy within 6 months.
  • For currently or previously treated WM patients (Cohort 2C):
    • Patient must not be currently taking a BTK inhibitor or had recent exposure within 1 month of enrollment. Current or prior history of any other WM-directed therapy is allowed.

Exclusion Criteria:
None listed

Additional Trial Information

Observational Trial

Enrollment: 160 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Brigham and Women's Hospital

Boston, MA

Not Yet Accepting

Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Massachusetts General Hospital to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors